LFSC
F/m Emerald Life Sciences Innovation ETF
Price Chart
Latest Quote
$45.79
-0.39 (-0.83%)
Current Price
| Previous Close | $46.18 |
| Open | $45.50 |
| Day High | $45.79 |
| Day Low | $45.30 |
| Volume | 4,431 |
Fund Information
| Net Assets | $124.88M |
| Expense Ratio | 0.54% |
| Category | Health |
| Fund Family | Emerald Mutual Fund Advisers Trust |
| Net Asset Value | $47.47 |
| Premium/Discount | -3.53% |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $47.20 |
| SMA50 | $46.00 |
| SMA200 | $39.06 |
| RSI | 39.16 |
| ATR | 0.7574 |
| Rel Volume | 1.20 |
Performance History
| Week | -4.19% |
| Month | -1.90% |
| Quarter | +16.25% |
| 6 Months | +25.87% |
| YTD | +26.42% |
| Year | +64.20% |
| 10 Years | +83.97% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $45.79 | 4,400 |
| 2026-08-27 | $47.50 | 2,700 |
| 2026-08-26 | $47.58 | 1,400 |
| 2026-08-25 | $48.06 | 4,600 |
| 2026-08-24 | $47.49 | 2,600 |
| 2026-08-21 | $47.79 | 3,100 |
| 2026-08-20 | $47.44 | 2,500 |
| 2026-08-19 | $48.44 | 6,500 |
| 2026-08-18 | $47.49 | 2,900 |
| 2026-08-17 | $47.42 | 6,800 |
| 2026-08-14 | $47.08 | 2,200 |
| 2026-08-13 | $46.82 | 1,800 |
| 2026-08-12 | $47.18 | 4,500 |
| 2026-08-11 | $46.79 | 5,000 |
| 2026-08-10 | $47.42 | 3,800 |
| 2026-08-07 | $47.26 | 2,900 |
| 2026-08-06 | $46.26 | 6,000 |
| 2026-08-05 | $47.44 | 2,600 |
| 2026-08-04 | $47.07 | 4,800 |
| 2026-08-03 | $45.62 | 2,500 |
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.